Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 54

Sort by

Sort Order Select

Journal Articles

Efficacy and safety of daratumumab plus carfilzomib-based induction/consolidation/maintenance therapy with autologous stem cell transplantation in transplant-eligible ultra high-risk newly diagnosed multiple myeloma: Preliminary results

Jian Xu, Jian Li, Yongqiang Wei, Weijun Fu, Bingzong Li, Xiu Li Sun, Kaini Shen, Xiaolei Wei, Lu Li, Liying Zhang, He Xu, Yueying Mao, Dehu Li, Aoshuang Xu, Fei Zhao, Chunyan Sun

Blood (2025) 146 (Supplement 1): 5828.

https://doi.org/10.1182/blood-2025-5828

Published: 2025

Journal Articles

A Phase II study of time-limited treatment with orelabrutinib plus bendamustine and obinutuzumab (OBG) in patients with treatment-Naïve CLL/SLL patients

Xutao Guo, Yunxia Zhang, Xiaolei Wei, Haohao Lei, Qi Wei, Yongqiang Wei, Dongsheng Wu, Ning Su, Ru Feng

Blood (2025) 146 (Supplement 1): 7417.

https://doi.org/10.1182/blood-2025-7417

Published: 2025

Journal Articles

Efficacy and safety of rocbrutinib, the fourth generation bruton's tyrosine kinase inhibitor, in patients with BTK inhibitor pre-treated relapsed or refractory Mantle Cell Lymphoma: Results from a Phase II rock-1 trial

Blood (2025) 146 (Supplement 1): 886.

https://doi.org/10.1182/blood-2025-886

Published: 2025

Journal Articles

Risk factors and outcomes of carbapenem-resistant and multidrug-resistant klebsiella pneumoniae bloodstream infection in patients with acute leukemia

Youhai Yuan, Shanshan Zhang, Yongqiang Wei, Ru Feng, Xiaolei Wei

Blood (2025) 146 (Supplement 1): 6930.

https://doi.org/10.1182/blood-2025-6930

Published: 2025

Journal Articles

A chemotherapy-free regimen of sintilimab, rituximab, and lenalidomide ± polatuzumab vedotin in elderly patients with newly diagnosed diffuse large B-cell lymphoma

Hanzhen Zhang, Xutao Guo, Qi Wei, Yongqiang Wei, Ru Feng, Xiaolei Wei

Blood (2025) 146 (Supplement 1): 5478.

https://doi.org/10.1182/blood-2025-5478

Published: 2025

Journal Articles

Efficacy and prognostic determinants of BTK inhibitors in chronic lymphocytic leukemia (CLL): A real-world single-center cohort study from China

Xutao Guo, Yongqiang Wei, Xiaolei Wei, Qi Wei, Ru Feng

Blood (2025) 146 (Supplement 1): 7421.

https://doi.org/10.1182/blood-2025-7421

Published: 2025

Journal Articles

Mutations in AMBRA1 aggravate β-thalassemia by impairing autophagy-mediated clearance of free α-globin

Blood (2025) 145 (10): 1074–1088.

https://doi.org/10.1182/blood.2023022688

Published: 2025

Includes: Supplemental data

Journal Articles

The Addition of Lenalidomide to R-CHOP Is Effective for Prevention of CNS Relapse in High-Risk Patients with Diffuse Large B-Cell Lymphoma

Xiaolei Wei, Xutao Guo, Qi Wei, Dan Xiong, Peng Zhang, Zewen Zhang, Yongqiang Wei, Ru Feng

Blood (2024) 144 (Supplement 1): 1740.

https://doi.org/10.1182/blood-2024-204915

Published: 2024

Journal Articles

Efficacy and Safety of a New Regime Containing PD1 Antibody and Pegaspargase for Advanced-Stage or Relapsed/Refractory Natural Killer/T Cell Lymphoma

Jie Chen, Linjun Zhao, Chongyang Wu, Haifeng Yu, Zhenling Li, Lihong Liu, Da Gao, Ying Sun, Xiaolei Wei, Yuanbin Wu, Yue Wang, Yuqin Song, Jun Zhu, Weiping Liu

Blood (2024) 144 (Supplement 1): 1686.

https://doi.org/10.1182/blood-2024-207412

Published: 2024

Journal Articles

Comparative Efficacy of Carfilzomib, Lenalidomide and Dexamethasone (KRD) Vs. Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRD) in Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis

Yuqi Wang, Chen Huan, Zhang Hanzhen, Shanshan Zhang, Youhai Yuan, Ru Feng, Yongqiang Wei, Xiaolei Wei

Blood (2024) 144 (Supplement 1): 7031.

https://doi.org/10.1182/blood-2024-205810

Published: 2024

Journal Articles

The Effectiveness of Low-Dose Decitabine Following Infusion of Autologous Hematopoietic Stem Cells in Patients Experiencing Persistent Pancytopenia after CD19-CART

Xutao Guo, Yunxia Zhang, Haohao Lei, Yongqiang Wei, Xiaolei Wei, Qi Wei, Ru Feng

Blood (2024) 144 (Supplement 1): 7249.

https://doi.org/10.1182/blood-2024-201948

Published: 2024

Journal Articles

Inhibition of PKM2 Promotes Chemosensitivity of DOX in ABC-DLBCL Via Imbalance of Gsh/ROS and Inhibition of the NF-ΚB Pathway

Yutian Yang, Minglang Zhan, Zhang Hanzhen, Xiaolei Wei, Yongqiang Wei, Ru Feng

Blood (2024) 144 (Supplement 1): 6244.

https://doi.org/10.1182/blood-2024-198161

Published: 2024

Journal Articles

Optimizing Time-Limited Therapy in Unfit CLL/SLL Patients: Orelabrutinib, Bendamustine, and Obinutuzumab Combination (OBG) Regimen

Xutao Guo, Xiaolei Wei, Yongqiang Wei, Qi Wei, Ning Su, Yunxia Zhang, Haohao Lei, Ru Feng

Blood (2024) 144 (Supplement 1): 6776.

https://doi.org/10.1182/blood-2024-207666

Published: 2024

Journal Articles

Ultrasound Exhibited Superior Advantages over 18F-FDG PET/CT in Monitoring Follow-up of DLBCL

Zhang Hanzhen, Yongqiang Wei, Xiaolei Wei, Ru Feng

Blood (2024) 144 (Supplement 1): 6456.

https://doi.org/10.1182/blood-2024-201377

Published: 2024

Journal Articles

Sintilimab, Rituximab and Lenalidomide (sR2) As First-Line Treatment in Elderly Patients with Diffuse Large B-Cell Lymphoma: A Single-Arm, Open-Label, Phase 2 Trial

Xiaolei Wei, Xutao Guo, Qi Wei, Yongqiang Wei, Ru Feng

Blood (2024) 144 (Supplement 1): 3121.

https://doi.org/10.1182/blood-2024-204940

Published: 2024

Journal Articles

EBV-Infected NKTCL Upregulated MHC-II Imprinted T Cell Exhaustion By Interacting with LAG3

Shanshan Zhang, Zhang Hanzhen, Chen Huan, Yuqi Wang, Youhai Yuan, Xiaolei Wei, Qifa Liu

Blood (2024) 144 (Supplement 1): 4372.

https://doi.org/10.1182/blood-2024-200751

Published: 2024

Journal Articles

Identification and Validation of High-Risk Genes Contributing to Poor Prognosis in Multiple Myeloma Patients with chr1q Gain/Amplification

Shanshan Zhang, Linjing Cai, Chen Huan, Yuqi Wang, Qifa Liu, Xiaolei Wei

Blood (2023) 142 (Supplement 1): 6601.

https://doi.org/10.1182/blood-2023-182883

Published: 2023

Journal Articles

The Addition of Lenalidomide to R-CHOP Is Effective for Prevention of CNS Relapse in High-Risk Patients with Diffuse Large B-Cell Lymphoma

Xiaolei Wei, Xutao Guo, Qi Wei, Dan Xiong, Peng Zhang, Zewen Zhang, Yongqiang Wei, Ru Feng

Blood (2023) 142 (Supplement 1): 6223.

https://doi.org/10.1182/blood-2023-182496

Published: 2023

Journal Articles

Metabolic Tumor Volume from Baseline PET/CT Improves Stratification in the High IPI Risk Patients with Diffuse Large B‐Cell Lymphoma

Zhang Hanzhen, Xiaolei Wei, Wenlan Zhou, Zihan Xu, Junjie Chen, Yongqiang Wei, Hubing Wu, Ru Feng

Blood (2023) 142 (Supplement 1): 3131.

https://doi.org/10.1182/blood-2023-177938

Published: 2023

Journal Articles

The Prognostic Value of Dynamic Change of NK-Cell Counts in Diffuse Large B-Cell Lymphoma Treated with R-CHOP

Chen Huan, Zhongxin Zheng, Yongqiang Wei, Xutao Guo, Qi Wei, Ru Feng, Xiaolei Wei

Blood (2023) 142 (Supplement 1): 6262.

https://doi.org/10.1182/blood-2023-181412

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Efficacy and safety of daratumumab plus carfilzomib-based induction/consolidation/maintenance therapy with autologous stem cell transplantation in transplant-eligible ultra high-risk newly diagnosed multiple myeloma: Preliminary results

A Phase II study of time-limited treatment with orelabrutinib plus bendamustine and obinutuzumab (OBG) in patients with treatment-Naïve CLL/SLL patients

Efficacy and safety of rocbrutinib, the fourth generation bruton's tyrosine kinase inhibitor, in patients with BTK inhibitor pre-treated relapsed or refractory Mantle Cell Lymphoma: Results from a Phase II rock-1 trial

Risk factors and outcomes of carbapenem-resistant and multidrug-resistant klebsiella pneumoniae bloodstream infection in patients with acute leukemia

A chemotherapy-free regimen of sintilimab, rituximab, and lenalidomide ± polatuzumab vedotin in elderly patients with newly diagnosed diffuse large B-cell lymphoma

Efficacy and prognostic determinants of BTK inhibitors in chronic lymphocytic leukemia (CLL): A real-world single-center cohort study from China

Mutations in AMBRA1 aggravate β-thalassemia by impairing autophagy-mediated clearance of free α-globin

The Addition of Lenalidomide to R-CHOP Is Effective for Prevention of CNS Relapse in High-Risk Patients with Diffuse Large B-Cell Lymphoma

Efficacy and Safety of a New Regime Containing PD1 Antibody and Pegaspargase for Advanced-Stage or Relapsed/Refractory Natural Killer/T Cell Lymphoma

Comparative Efficacy of Carfilzomib, Lenalidomide and Dexamethasone (KRD) Vs. Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRD) in Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis

The Effectiveness of Low-Dose Decitabine Following Infusion of Autologous Hematopoietic Stem Cells in Patients Experiencing Persistent Pancytopenia after CD19-CART

Inhibition of PKM2 Promotes Chemosensitivity of DOX in ABC-DLBCL Via Imbalance of Gsh/ROS and Inhibition of the NF-ΚB Pathway

Optimizing Time-Limited Therapy in Unfit CLL/SLL Patients: Orelabrutinib, Bendamustine, and Obinutuzumab Combination (OBG) Regimen

Ultrasound Exhibited Superior Advantages over 18F-FDG PET/CT in Monitoring Follow-up of DLBCL

Sintilimab, Rituximab and Lenalidomide (sR2) As First-Line Treatment in Elderly Patients with Diffuse Large B-Cell Lymphoma: A Single-Arm, Open-Label, Phase 2 Trial

EBV-Infected NKTCL Upregulated MHC-II Imprinted T Cell Exhaustion By Interacting with LAG3

Identification and Validation of High-Risk Genes Contributing to Poor Prognosis in Multiple Myeloma Patients with chr1q Gain/Amplification

The Addition of Lenalidomide to R-CHOP Is Effective for Prevention of CNS Relapse in High-Risk Patients with Diffuse Large B-Cell Lymphoma

Metabolic Tumor Volume from Baseline PET/CT Improves Stratification in the High IPI Risk Patients with Diffuse Large B‐Cell Lymphoma

The Prognostic Value of Dynamic Change of NK-Cell Counts in Diffuse Large B-Cell Lymphoma Treated with R-CHOP

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only